🇯🇵·17h agoIndustry
European Commission Approves PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) as the First and Only Approved Perioperative Treatment Option for Cisplatin-Ineligible Patients with Resectable Muscle-Invasive Bladder Cancer
Publisher
A
Astellas Pharma
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Astellas Pharma
- Region
- Japan
- Scope
- Industry
- Published
- June 24, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on newsroom.astellas.com
Leave the platform to read the original full article on the publisher site.
Source: Astellas Pharma
Scope: Industry
Related coverage
More related coverage
Eli Lilly News/3h ago
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
GSK News/4h ago
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
AbbVie News/4h ago
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
Aspen Pharmacare/5h ago